

# TABLE OF CONTENTS

<b>LIST OF TABLES</b>	<b>vii</b>
<b>LIST OF FIGURES</b>	<b>ix</b>
<b>EXECUTIVE SUMMARY AND HIGHLIGHTS</b>	<b>1</b>
<b>1. MARKET</b>	<b>13</b>
1.1 Scope, definitions and segmentation	13
1.2 Market size by value	14
1.2.1 Recent trends in acute medical/surgical hospital market value	16
1.2.2 Recent trends in clinics and privately practising doctor market value	17
1.2.3 Market value by region	17
1.3 Market size by resources	18
1.3.1 Acute medical/surgical hospitals and day surgery units	18
1.3.2 Clinics	19
1.3.3 Privately practising doctors	22
1.3.3.1 Future supply of private practice	23
1.4 Market size by activity	25
1.4.1 PHIN activity data	25
1.4.2 PHIN data coverage	26
1.4.3 Disparity between boundaries of PHIN data collection and LaingBuisson market segmentation	26
1.4.4 Leading procedures by volume	27
1.4.5 Leading providers by volume of procedures	28
1.5 Some major sub-segments within the independent ‘clinic’ sector	29
1.5.1 Cataract surgery	29
1.5.2 Cosmetic/aesthetic procedures	31
1.5.3 Diagnostics	31
1.5.4 Cancer	32
1.5.5 Screening	33
1.5.6 Abortions	33
1.6 Sources of funding of private acute healthcare	34
1.7 Growth trends and drivers of growth	35
1.8 Four segments of public and private finance and supply	38
1.9 Performance indicators	39
1.9.1 Profitability	39

1.9.2	Quality indicators – CQC ratings	39
1.10	Dissatisfaction with the NHS – a potent driver of private healthcare expansion?	42
<b>2.</b>	<b>POLITICS, LEGISLATION AND POLICY</b>	<b>45</b>
2.1	Overview	45
2.1.1	Direct impacts	45
2.1.2	Indirect impacts	45
2.2	Covid-19 and the impact on the healthcare system (2020–2021)	46
2.2.1	Overview of key events (March 2020–August 2021)	47
2.2.2	Covid-19 and the impact on the independent sector’s relationship with the NHS	50
2.3	Returning to normality: Key government legislation and policy developments post-Covid-19	51
2.3.1	The Health and Care Act (2022) – Background context	51
2.3.1.1	Integrated care and a shift from competition to collaboration	51
2.3.1.2	Provider Selection Regime: Removing healthcare commissioning from the requirements of Public Contracts Regulations 2015	53
2.3.1.3	Patient choice	54
2.3.1.4	New powers for the Secretary of State for Health and Social Care	55
2.3.2	Build Back Better: Plans for the NHS after the pandemic	55
2.3.3	Elective recovery	56
2.3.3.1	Funding the elective recovery programme	56
2.3.3.2	Tackling the Covid-19 backlog: Working with the independent sector	57
2.3.3.3	Community diagnostic centres (CDC): Moving testing out of NHS hospitals	57
2.3.3.4	My Planned Care: Improving patient choice through transparency	58
2.3.3.5	Elective recovery implementation plan	58
2.4	The Labour party and its position on the role of independent healthcare	59
2.5	Key impacts from government policy	59
2.6	Historic government policy	61
2.6.1	Emergence and development of private acute medical care, 1973–1997	61
2.6.2	Philosophical opposition to private healthcare under Labour, 1997–2000	62
2.6.3	Engaging the independent sector to upscale NHS performance, 2000–2010	62
2.6.4	The Coalition government – reforms in action, 2010–2015	63
2.6.5	Political environment for the NHS under Theresa May	64
<b>3.</b>	<b>REGULATION OF THE INDEPENDENT HEALTHCARE SECTOR</b>	<b>67</b>
3.1	Overview	67
3.1.1	Areas of regulatory concern	68

3.1.2	Care Quality Commission and the regulation of healthcare providers	68
3.1.2.1	Independent providers and the scope of regulated activities in England	69
3.1.2.2	Registration	71
3.1.2.3	The inspection process	71
3.1.2.4	Quality ratings and independent sector performance	73
3.1.2.5	Enforcement	74
3.1.3	Regulation during Covid-19	75
3.1.4	An evolving model: Key regulatory changes expected from 2023	76
3.1.4.1	Cosmetic services: Existing on the edge of regulation	77
3.2	The quality agenda	79
3.2.1	The Paterson Inquiry: Recommendations and an update on their implementation	79
3.2.2	Quality and safety: Improvements in the independent sector	80
3.3	Competition investigations	82
3.3.1	Competition regulation and the independent healthcare market	82
3.3.2	Competition regulation and concerns over a fair and competitive market in private healthcare provision	82
3.3.2.1	CMA Investigation into the competitiveness of the private acute healthcare market	83
3.3.2.2	Sector challenges to CMA findings and a review of the recommendations	84
3.3.2.3	Sector engagement on required data transparency and the risk of CMA enforcement action	85
3.3.2.4	The impact on the private healthcare market of the CMA actions	85
3.3.3	Circle and the acquisition of BMI: Competition concerns over local market dominance	86
3.3.4	Private ophthalmology services: Anti-competitive activity in consultation fee setting	86
3.3.5	Fertility services: A focus on ensuring consumers can make informed choices	86
<b>4.</b>	<b>PAYORS</b>	<b>89</b>
4.1	Sources of funding for private acute healthcare	89
4.1.1	Acute medical/surgical hospitals	89
4.1.1.1	Activity by sources of funding	89
4.1.1.2	Market value by sources of funding	89
4.2	Private medical cover	92
4.2.1	Trends in private medical cover payouts to private acute healthcare providers	92

4.2.2	Interdependence of private medical cover and private acute healthcare	93
4.3	NHS purchasing	94
4.3.1	Trends in NHS purchasing	94
4.3.2	Future prospects for NHS purchasing	96
4.4	Self-pay	98
4.4.1	Self-pay trends	98
4.4.2	Consumer driven spending on private healthcare	100
4.5	Overseas and embassy funding	101
4.5.1	Overseas patient trends	101
4.6	Private patients only (PPO) hospital market	103
<b>5.</b>	<b>MAJOR PROVIDERS</b>	<b>105</b>
5.1	Independent sector – market concentration and shares	105
5.2	Independent acute healthcare – provider type	110
5.2.1	Overseas ownership	110
5.2.2	For-profit and not-for-profit ownership	111
5.3	Market shaping – structural changes impacting providers	112
5.4	Diversification of services	113
5.5	Independent acute medical healthcare facilities	114
5.5.1	Overview of investment in new facility developments since 2014	114
5.5.2	Full-service and specialist inpatient acute hospitals	118
5.5.3	Day surgery only (including specialist facilities)	120
5.5.4	Specialist outpatient clinics	121
5.5.5	Capital investment by incumbents	123
5.6	Independent acute eyecare facilities	124
5.6.1	Investment in new capacity (2021–2023)	124
5.6.2	Historic investment in capacity development in independent eyecare facilities	125
5.7	Other independent acute markets	129
5.7.1	Screening	129
5.7.2	Fertility	130
5.7.3	Pregnancy terminations	131
5.7.4	Insourcing of independent sector services into the NHS	131
5.7.5	Independent sector management of NHS acute services	133
5.8	NHS providers – private income market shares	134
5.8.1	Specialisation	137
5.8.2	New NHS private patient facilities, including partnerships	138

<b>6.</b>	<b>INVESTORS</b>	<b>141</b>
6.1	Major investor review	141
6.2	Investment in the independent sector: The case after Covid-19	143
6.3	Investment activity (2021–2023)	144
6.4	Past investment activity (2015–2020)	145
6.5	Sector focus areas for investors	148
6.5.1	Investors in diagnostics	148
6.5.2	Investors in ophthalmology	149
6.5.3	Investors in the fertility sector	149
6.6	Private equity investor profiles	150
6.6.1	Apposite Capital	150
6.6.2	Bluegem Capital	151
6.6.3	Bridgepoint	151
6.6.4	CBPE	152
6.6.5	China Resources	152
6.6.6	EQT	153
6.6.7	G Square Capital	153
6.6.8	H2 Equity Partners	154
6.6.9	IK Partners	154
6.6.10	MidEuropa	155
6.6.11	NorthWest Healthcare Properties REIT	155
6.6.12	Primary Healthcare Properties plc REIT	156
6.6.13	PureHealth	156
6.6.14	Nordic Capital	157
6.6.15	Quadrivio Group	157
6.6.16	Trispan	158
<b>7.</b>	<b>MARKET POTENTIAL</b>	<b>159</b>
7.1	Market forecasts	159
7.2	Market potential commentary	160
7.2.1	High waiting lists and an upcoming general election should lead to continued growth in NHS-funded care. However, local pushback may remain a dampener on use of the independent sector	160
7.2.2	Self-funding volumes have the potential to grow but not at the rate seen in the immediate post-pandemic period	161
7.2.3	Younger people are becoming more comfortable accessing private healthcare, and are likely to be self-funders and accessing lower-cost procedures	162

7.2.4	Opportunities exist to improve awareness of private healthcare costs and financing options	162
7.2.5	Health coverage expected to continue to grow but increase in claims may drive pressure on premiums, impacting coverage	163
7.2.6	Investment in day case capacity is likely to grow to meet clinical and financial drivers for reducing inpatient beds when they are not clinically necessary	163
7.2.7	Longer-term trends that have seen the funding mix shift towards self-pay from health coverage is expected to continue	163
7.2.8	Continued clinics growth amid ongoing private equity interest	164
7.2.9	Insourcing will continue to grow, likely ending up as another part of the market – but will bring challenges with perception for NHS Trusts	164
7.2.10	Business as usual – the independent sector under a Labour administration	165

**APPENDIX 1. GLOSSARY 167**

**APPENDIX 2. REGULATORS 171**

**APPENDIX 3. TRADE BODIES AND ASSOCIATIONS 173**

**APPENDIX 4. MAJOR INDEPENDENT HEALTHCARE PROVIDERS 175**

**APPENDIX 5. LIST OF DEDICATED NHS PAY BED UNITS 205**

**APPENDIX 6. FINANCIAL APPENDIX 209**

## LIST OF TABLES

Table ES.1	Market size of UK hospitals and clinics in 2022, and projections for 2023–2025	5
Table 1.1	Private acute medical/surgical hospital market value (independent acute medical/surgical hospitals and NHS PPUs), UK, 2003–2022	16
Table 1.2	NHS private patient revenues <sup>1</sup> , by region, UK, 2018/19–2021/22	17
Table 1.3	Acute medical/surgical hospital and day surgery capacity in facilities with operating theatres equipped for general anaesthesia, independent sector and NHS private patient units, UK, 1981–2023	18
Table 1.4	Regional breakdown of independent acute medical/surgical hospital capacity, UK, September 2023	19
Table 1.5	Regional breakdown of NHS PPUs, UK, September 2023	20
Table 1.6	Independent sector clinics registered by CQC in England by primary specialism, September 2023	21
Table 1.7	Private episodes of admitted patient care in UK independent sector and NHS hospitals (PHIN data), calendar 2022, by type of hospital facility and funding source	26
Table 1.8	Top ten private procedures (delivered in independent sector facilities), by episode volume, reported by PHIN, UK, 2019–22	28
Table 1.9	Leading independent sector providers by volume of episodes reported to PHIN, UK calendar 2022	28
Table 1.10	Cataract surgery procedures year ending March 2023 and most recent provider revenues, UK	30
Table 1.11	Latest EBITDAR margin and pre-tax profit/loss margin for major private acute healthcare operating companies	40
Table 3.1	Regulated activities: Independent acute medical care sector	70
Table 3.2	Overall CQC quality ratings of core services for NHS hospitals and independent sector acute hospitals	74
Table 4.1	Independent acute medical/surgical hospital market share by funding source, UK, 2003–2022	91
Table 5.1	Independent sector acute medical care providers by provider grouping, UK, July 2023	106
Table 5.2	Capacity of major acute medical care hospital operators by number of inpatient and day surgery hospitals, overnight beds, and total operating theatres in all facilities, September 2023	108
Table 5.3	Market shares of leading providers of independent acute medical/surgical hospitals and NHS private patient units, UK, 2022	109
Table 5.4	New independent acute medical care facilities by region, service type (full-service or specialist) and treatment type (Inpatient/Day/Outpatient), UK, from 2015 onwards	115
Table 5.5	Future new independent acute medical care facilities in the UK by region, service type (full-service or specialist) and treatment type	118
Table 5.6	New independent acute eyecare facilities by region, service type, and treatment type (Inpatient/Day/Outpatient), UK, from 2015 onwards	126

Table 5.7	Revenues of leading specialist IVF providers, £m, UK, 2015–2022	130
Table 5.8	Insourcing providers to the NHS	133
Table 5.9	Top 30 NHS Trusts by private patient revenue 2018/19–2021/22	135
Table 6.1	Main investors in the UK private acute medical care market, including source country, and investment start, May 2023	142
Table 6.2	Significant acquisitions in the UK private acute hospital and clinics market, 2015 onwards	146
Table 7.1	Market forecasts	159
Table A5.1	List of dedicated NHS pay bed inpatient units, by region, and management type, June 2023	205
Table A5.2	List of dedicated NHS pay bed day/outpatient units, by region, and management type, June 2023	208



## LIST OF FIGURES

Figure ES1	Segmental analysis of the private acute healthcare market value by broad segment, UK, 2022	3
Figure ES2	Private acute healthcare market value, by source of funding, UK, 2022	4
Figure 1.1	Private acute healthcare services segmentation, UK	13
Figure 1.2	Segmental analysis of the private acute healthcare market value by broad segment, UK, 2022	14
Figure 1.3	Independent sector capacity indicators (hospitals, overnight beds and operating theatres), by sub-region in London and the South East, June 2023	20
Figure 1.4	Active consultants in private healthcare (PHIN data), UK, January 2019–December 2022	22
Figure 1.5	Segmentation of abortion procedures by provider sector and funding source, England and Wales residents, 2021	33
Figure 1.6	Legal abortions carried out in England and Wales, 1968–2021	34
Figure 1.7	Private acute healthcare market value, by source of funding, UK, 2022	35
Figure 1.8	Independent acute medical/surgical hospital market value by funding source, £m, UK, 2003–2022	36
Figure 1.9	UK hospital (inpatient and day case) admissions activity breakdown by type of hospital supply (public NHS or private) and type of funding (public NHS or private), 1986–2021/22	38
Figure 1.10	EBITDAR margin of leading independent sector hospital groups, 2008–2022	41
Figure 1.11	Overall CQC quality ratings of core services for NHS hospitals and independent sector acute hospitals	41
Figure 1.12	Public satisfaction and dissatisfaction ‘with the way in which the NHS runs nowadays’, 1983–2022	42
Figure 1.13	NHS waiting list and waiting times for patients waiting to start treatment at the end of the month (incomplete pathways), and average (median) time waited, England, August 2007–May 2023	43
Figure 1.14	Private medical cover subscribers/enrolees, UK, 1975–2021	43
Figure 4.1	Independent acute medical/surgical sector activity (admitted patient care) by source of funding, UK, 2022	89
Figure 4.2	Independent acute medical/surgical hospitals market value by source of funding, UK 2022	90
Figure 4.3	Clinics and privately practising doctors market segmentation by source of funding, UK, 2022	91
Figure 4.4	Private medical cover payouts (insured and self-insured medical expenses schemes), UK, 1995–2022	92
Figure 4.5	Value of NHS purchasing from independent acute medical/surgical hospitals in the UK, and NHS funded admissions to independent hospitals and clinics in England (2003–2022)	95
Figure 4.6	NHS funded acute medical care hospital admissions to independent sector facilities, by provider, England, 2022/23	96

Figure 4.7	Share of NHS funded episodes carried out by independent sector by type of specialty, England, 2022/23	97
Figure 4.8	Self-pay funding of independent acute medical/surgical hospitals, UK, 2003–2022	99
Figure 4.9	PHIN's quarterly private inpatient and day case admission activity, Q1 2019–Q1 2023	99
Figure 4.10	Value of consumer driven demand for private acute healthcare: self-pay revenue + individual paid private medical insurance payouts, £m as 2022 prices after deflation by CPI, UK, 2003–2022	101
Figure 4.11	Value of overseas demand for medical/surgical hospital services, UK, 2003–2022	102
Figure 4.12	Independent acute medical/surgical hospital real terms market value, PPO, £m as 2022 prices after deflation by CPI, UK, 2003–2022	104
Figure 5.1	Market shares of private acute medical care hospital market (independent sector hospitals + NHS private patient revenues) by provider, UK, 2022	106
Figure 5.2	Market shares of top eight independent sector hospital providers in PPO acute medical care market, UK, 2021	111